Rehovot, Israel, March 20, 2024 (ots/PRNewswire) – Data published in The Lancet Neurology show favorable efficacy of ND0612 compared to immediate-release oral levodopa/carbidopa NeuroDerm Ltd, a wholly owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), today announced the publication of the results of the pivotal Phase 3 BouNDless study (NCT04006210) in The Lancet Neurology […]
NeuroDerm announces the release of positive results from the Phase 3 BouNDless study evaluating ND0612 in patients with Parkinson's disease motor fluctuations
